Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Labels:
#health
No comments
Read More About This Article: https://ift.tt/NUns4va
Subscribe to:
Post Comments
(
Atom
)
No comments :
Post a Comment